KIR3DL1 and neoplasm: For instance, in patients with non‐Hodgkin lymphoma, a limited presence of KIR ligands promotes the expansion of “educated” KIR+ NK cells, which enhance the therapeutic efficacy of rituximab by facilitating tumor cell killing.